13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0002106939
Total reported value
$145.8M
$145.8M
75 檔
111.4%
In Q2 2026, PSP Research LLC's U.S. equity holdings reached a combined market value of $145.8M, distributed across 75 disclosed stock positions.
In Q2 2026, PSP Research LLC adopted a defensive or profit-taking posture, trimming 30 positions and completely liquidating 15 holdings to manage risk exposure.
In terms of portfolio concentration, the top 5 core holdings (including XBI, SGOV, RPRX) accounted for 111.4% of total reported equity market value during Q2 2026.
Top New Position Initiated
ASCENDIS PHARMA A/S
市值: $400.1K
Top Position Liquidated / Trimmed
SERA
前期市值: $4.9M
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 48.01% | -6.22% | +100.07% | |
| 2 | SGOV | Ishares 0-3 Month Treasury B | ETF-Gov Bonds | 37.51% | +10.82% | — | |
| 3 | RPRX | Royalty Pharma plc | Stock-Healthcare | 0.33% | -0.13% | — | |
| 4 | NRIX | Nurix Therapeutics Inc | Stock-Other | 0.32% | -0.12% | -12.89% | |
| 5 | INCY | Incyte CORP | Stock-Healthcare | 0.32% | -0.15% | — | |
| 6 | ARGX | Argenx Se - Adr | Stock-Healthcare | 0.32% | -0.12% | — | |
| 7 | IRON | Disc Medicine Inc | Stock-Other | 0.31% | -0.31% | EXIT | |
| 8 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.31% | -0.31% | EXIT | |
| 9 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.30% | -0.30% | EXIT | |
| 10 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.30% | -0.15% | — | |
| 11 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.30% | -0.30% | EXIT | |
| 12 | TGTX | Tg Therapeutics Inc | Stock-Healthcare | 0.29% | -0.10% | -23.08% | |
| 13 | HALO | Halozyme Therapeutics Inc | Stock-Healthcare | 0.29% | -0.06% | -12.78% | |
| 14 | IONS | Ionis Pharmaceuticals Inc | Stock-Healthcare | 0.29% | -0.29% | EXIT | |
| 15 | PHVS | Pharvaris N.V. | Stock-Other | 0.28% | -0.28% | EXIT | |
| 16 | ARQT | Arcutis Biotherapeutics Inc | Stock-Other | 0.27% | -0.09% | — | |
| 17 | AUPH | Aurinia Pharmaceuticals Inc | Stock-Other | 0.27% | -0.10% | — | |
| 18 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 0.27% | -0.09% | -22.04% | |
| 19 | IMVT | Immunovant Inc | Stock-Other | 0.27% | -0.11% | -32.29% | |
| 20 | ACAD | Acadia Pharmaceuticals Inc | Stock-Healthcare | 0.27% | -0.27% | EXIT | |
| 21 | PTCT | Ptc Therapeutics Inc | Stock-Healthcare | 0.26% | -0.26% | EXIT | |
| 22 | CLDX | Celldex Therapeutics Inc | Stock-Other | 0.26% | -0.26% | EXIT | |
| 23 | IMCR | Immunocore Holdings Plc-adr | Stock-Other | 0.26% | -0.11% | — | |
| 24 | DFTX | Definium Therapeutics Inc | Stock-Other | 0.25% | -0.08% | -71.26% | |
| 25 | COGT | Cogent Biosciences Inc | Stock-Other | 0.25% | -0.25% | EXIT | |
| 26 | KYMR | Kymera Therapeutics Inc | Stock-Other | 0.24% | -0.09% | -36.51% | |
| 27 | DYN | Dyne Therapeutics Inc | Stock-Other | 0.24% | -0.13% | — | |
| 28 | ALNY | Alnylam Pharmaceuticals Inc | Stock-Healthcare | 0.23% | -0.23% | EXIT | |
| 29 | TARS | Tarsus Pharmaceuticals Inc | Stock-Other | 0.23% | -0.04% | — | |
| 30 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 0.23% | -0.08% | — | |
| 31 | EXEL | Exelixis Inc | Stock-Healthcare | 0.23% | -0.03% | -33.04% | |
| 32 | CRNX | Crinetics Pharmaceuticals In | Stock-Other | 0.22% | -0.22% | EXIT | |
| 33 | NAMS | NewAmsterdam Pharma Company N.V. | Stock-Other | 0.22% | -0.22% | EXIT | |
| 34 | ✓ | Ascendis Pharma A/s | Stock-Other | 0.21% | -0.05% | — | |
| 35 | LQDA | Liquidia CORP | Stock-Other | 0.21% | -0.21% | EXIT | |
| 36 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.21% | -0.05% | — | |
| 37 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.21% | -0.21% | EXIT | |
| 38 | IMNM | Immunome Inc | Stock-Other | 0.20% | -0.02% | -10.00% | |
| 39 | PTGX | Protagonist Therapeutics Inc | Stock-Other | 0.20% | -0.06% | — | |
| 40 | HRMY | Harmony Biosciences Holdings | Stock-Other | 0.19% | — | -29.99% | |
| 41 | ELVN | Enliven Therapeutics Inc | Stock-Other | 0.19% | -0.19% | EXIT | |
| 42 | SYRE | Spyre Therapeutics Inc | Stock-Other | 0.19% | -0.19% | EXIT | |
| 43 | NTLA | Intellia Therapeutics Inc | Stock-Other | 0.18% | -0.01% | -25.65% | |
| 44 | MDGL | Madrigal Pharmaceuticals Inc | Stock-Healthcare | 0.17% | +0.04% | — | |
| 45 | KNSA | Kiniksa Pharmaceuticals International, plc | Stock-Other | 0.17% | +0.01% | -44.44% | |
| 46 | ALKS | Alkermes plc | Stock-Healthcare | 0.17% | — | — | |
| 47 | TNGX | Tango Therapeutics Inc | Stock-Other | 0.17% | — | -30.56% | |
| 48 | ARDX | Ardelyx Inc | Stock-Other | 0.16% | -0.09% | -25.00% | |
| 49 | VERA | Vera Therapeutics Inc | Stock-Other | 0.16% | -0.16% | EXIT | |
| 50 | MIRM | Mirum Pharmaceuticals Inc | Stock-Other | 0.16% | -0.01% | -50.00% |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | XBI | Ss Spdr S&p Biotech ETF | +22.3% | +100.07% | Add |
| 2 | ✓ | Ascendis Pharma A/s | +0.2% | NEW | New buy |
| 3 | LQDA | Liquidia CORP | +0.2% | NEW | New buy |
| 4 | KRYS | Krystal Biotech Inc | +0.1% | NEW | New buy |
| 5 | AVBP | Arrivent Biopharma Inc | +0.1% | NEW | New buy |
| 6 | JAZZ | Jazz Pharmaceuticals plc | +0.1% | NEW | New buy |
| 7 | RVMD | Revolution Medicines Inc | +0.1% | NEW | New buy |
| 8 | RYTM | Rhythm Pharmaceuticals Inc | +0.1% | NEW | New buy |
| 9 | DNLI | Denali Therapeutics Inc | +0.1% | NEW | New buy |
| 10 | ARWR | Arrowhead Pharmaceuticals In | +0.1% | NEW | New buy |
| 11 | SRRK | Scholar Rock Holding CORP | +0.1% | NEW | New buy |
| 12 | CTMX | Cytomx Therapeutics Inc | +0.1% | NEW | New buy |
| 13 | TRVI | Trevi Therapeutics Inc | +0.1% | — | Unchanged |
| 14 | ALKS | Alkermes plc | 0% | — | Unchanged |
| 15 | NRIX | Nurix Therapeutics Inc | 0% | -12.89% | Trim |
| 16 | SYRE | Spyre Therapeutics Inc | 0% | -22.47% | Trim |
| 17 | RAPP | Rapport Therapeutics Inc | — | — | Unchanged |
| 18 | ELVN | Enliven Therapeutics Inc | — | — | Unchanged |
| 19 | ARGX | Argenx Se - Adr | 0% | — | Unchanged |
| 20 | AMLX | Amylyx Pharmaceuticals Inc | 0% | — | Unchanged |
| 21 | OCUL | Ocular Therapeutix Inc | 0% | — | Unchanged |
| 22 | EYPT | Eyepoint Inc | 0% | — | Unchanged |
| 23 | TGTX | Tg Therapeutics Inc | 0% | -23.08% | Trim |
| 24 | DYN | Dyne Therapeutics Inc | 0% | — | Unchanged |
| 25 | PTGX | Protagonist Therapeutics Inc | 0% | — | Unchanged |
| 26 | ORKA | Oruka Therapeutics Inc | 0% | -39.61% | Trim |
| 27 | RARE | Ultragenyx Pharmaceutical In | 0% | -23.08% | Trim |
| 28 | INCY | Incyte CORP | 0% | — | Unchanged |
| 29 | GLUE | Monte Rosa Therapeutics Inc | 0% | -17.86% | Trim |
| 30 | PTCT | Ptc Therapeutics Inc | 0% | — | Unchanged |
| 31 | CLDX | Celldex Therapeutics Inc | 0% | — | Unchanged |
| 32 | EWTX | Edgewise Therapeutics Inc | 0% | -23.08% | Trim |
| 33 | RPRX | Royalty Pharma plc | 0% | — | Unchanged |
| 34 | AUPH | Aurinia Pharmaceuticals Inc | 0% | — | Unchanged |
| 35 | ACAD | Acadia Pharmaceuticals Inc | 0% | — | Unchanged |
| 36 | OLMA | Olema Pharmaceuticals Inc | 0% | — | Unchanged |
| 37 | TNGX | Tango Therapeutics Inc | 0% | -30.56% | Trim |
| 38 | ZYME | Zymeworks Inc | 0% | — | Unchanged |
| 39 | XENE | Xenon Pharmaceuticals Inc | 0% | — | Unchanged |
| 40 | IRON | Disc Medicine Inc | -0.1% | — | Unchanged |
| 41 | ORIC | Oric Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 42 | MDGL | Madrigal Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 43 | ARQT | Arcutis Biotherapeutics Inc | -0.1% | — | Unchanged |
| 44 | IMCR | Immunocore Holdings Plc-adr | -0.1% | — | Unchanged |
| 45 | CRNX | Crinetics Pharmaceuticals In | -0.1% | — | Unchanged |
| 46 | NTLA | Intellia Therapeutics Inc | -0.1% | -25.65% | Trim |
| 47 | SUPN | Supernus Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 48 | IONS | Ionis Pharmaceuticals Inc | -0.1% | — | Unchanged |
| 49 | IMVT | Immunovant Inc | -0.1% | -32.29% | Trim |
| 50 | STOK | Stoke Therapeutics Inc | -0.1% | — | Unchanged |
According to official SEC Form 13F filings, PSP Research LLC reported a total U.S. public equity portfolio value of $145.8M across 75 disclosed positions in Q2 2026.
During Q2 2026, PSP Research LLC's top holdings by market value included XBI (48.0%)、SGOV (37.5%)、RPRX (0.3%). The largest single position, XBI, represented 48.0% of total portfolio value.
In Q2 2026, PSP Research LLC made 57 total portfolio adjustments, initiating 11 new buys, adding to 1 positions, trimming 30 holdings, and fully liquidating 15 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.